Oxalóza u nemocných v pravidelném dialyzacním lécení
[Oxalosis in patients on regular dialysis therapy]
Jazyk čeština Země Česko Médium print
Typ dokumentu kazuistiky, anglický abstrakt, časopisecké články
PubMed
1413575
- MeSH
- dialýza ledvin škodlivé účinky MeSH
- kardiomyopatie etiologie metabolismus MeSH
- kožní nemoci etiologie metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- nemoci kostí etiologie metabolismus MeSH
- šťavelan vápenatý metabolismus MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- anglický abstrakt MeSH
- časopisecké články MeSH
- kazuistiky MeSH
- Názvy látek
- šťavelan vápenatý MeSH
The authors draw attention to the case of a 46-year-old man who developed after three years of regular dialyzation treatment three times a week the first manifestations of acquired generalized oxalosis. The oxalosis was most marked on the skin, skeleton, heart, and kidneys. Oxalosis was confirmed after eight years of dialysis after death by post-mortem and histological examination and microscopic detection of oxalate crystals. The authors recommend that as part of regular dialyzation treatment patients should not be given more than 100 mg ascorbic acid per day. Oxalates are also the end product of degradation of ascorbic acid and high doses may lead also to hyperoxalosis. Moreover deposits in some visceral organs, in particular the heart may cause clinical manifestations. In the authors patients they caused attacks of auricular flutter. Although these clinical manifestations develop only rarely, the latent form of acquired oxalosis is probably more frequent.